BDSX biodesix.com: Total Company Value-to-Revenue Ratio

biodesix.com (BDSX) - corporate logo

Biodesix, Inc. (BDSX) is scaling the implementation of precision liquid biopsies, expanding its B2B segment in the US. The EV/Revenue ratio on the base GURU.Markets chart shows signs of market equilibrium, while 1292.27 determines the latest valuation metric. High diagnostic speed allows the company to exercise pricing power. Stable demand for tests ensures the company consistently covers all operating and research expenses.

Biodesix, Inc. (BDSX) - EV/Sales Multiple from 11/23/2025 to 11/20/2026

Biodesix, Inc. - analytical breakdowns and key metrics (BDSX)

- market price and analyst price targets:
Fundamental company valuation:BDSX, biodesix.com
Core merchandise of Biodesix Corporation

This ratio compares the total enterprise value, including debt, to the volume of generated revenue, determining the market price per unit of sales. For Biodesix, Inc. (BDSX), whose molecular diagnostic laboratories are operating at full capacity, this metric reflects the capitalization efficiency of high-tech processes, allowing investors to assess the investment attractiveness of assets through the EV/Sales multiple trend.